Shot of a young woman having a consultation with a doctor

RESOURCES FOR GUIDELINE-DRIVEN PrEP SCREENING

PrEP

Pre-exposure prophylaxis (PrEP), in combination with safe sex practices, reduces the chance of being infected with HIV for individuals at risk.1 To maximize PrEP’s preventive benefits, it is crucial to follow CDC screening guidelines, which include regular HIV testing, among other tests.2 At Labcorp, we offer the latest CDC-compliant PrEP baseline and monitoring panels for oral and injectable PrEP, helping you minimize unnecessary out-of-pocket costs so you can focus on what matters most: your patients.

Meeting your PrEP testing needs, from baseline and beyond

Whether your patients are initiating PrEP medication for the first time, reinitiating after a long stop, have recently taken PrEP or have been taking the medication for years, the CDC recommends routine testing to help prevent HIV infection.3

At Labcorp, we offer CDC-compliant screening panels for all of your patients’ PrEP testing needs.

Learn more about the CDC’s update on HIV PrEP guidelines.

Read Now »

Explore our PrEP test panels.

Learn More »

Federal requirements for insurance coverage of PrEP testing panels help minimize out-of-pocket costs.

Learn More »

According to the CDC, PrEP has been shown to be safe and effective in reducing the risk of HIV infection in adults without acute or established HIV.2 The CDC recommends PrEP for:

All sexually active adults and adolescents who report sexual behaviors that place them at risk of HIV exposure and acquisition.

This includes persons who have had anal or vaginal sex in the past 6 months AND any of the following: an HIV-positive sexual partner, a bacterial STI in the past 6 months, or a history of inconsistent or no condom use with sexual partners.

Adults and adolescents who inject drugs and report injection practices that place them at risk of HIV exposure and acquisition.

This includes persons sharing injection equipment or having an HIV-positive injecting partner.

References

  1. TRUVADA (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use [package insert]. Initial US approval 2004. Foster city, Calif: Gilead Sciences Inc; April 2017. Revised May 2018.
  2. US Public Health Service; Preexposure prophylaxis for the prevention of HIV infection in the United States – 2021 A clinical practice guideline. Available at https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed December 22, 2022.
  3. Centers for Disease Control and Prevention (CDC). Pre-Exposure Prophylaxis (PrEP) Quick Guide: 2021 PrEP Update. https://www.cdc.gov/hiv/clinicians/prevention/prep.html. Accessed December 30, 2022.
  4. Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. cdc.gov. Accessed January 22, 2019. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf